Keyphrases
Patient Selection
100%
PD-1 Blockade
100%
PD-L1 Expression
100%
PD-L1 Blockade Therapy
100%
Cell Lung Cancer
100%
Programmed Death-ligand 1 (PD-L1)
75%
Cancer Therapy
25%
Treatment Response
25%
Renal Cell Carcinoma
25%
Immunohistochemistry
25%
Clinical Trials
25%
Monotherapy
25%
T Cells
25%
Novel Therapeutics
25%
T Cell Receptor
25%
In Cancer
25%
Non-small Cell Lung Cancer (NSCLC)
25%
Clonality
25%
Solid Tumors
25%
Durable Response
25%
Tumor Microenvironment
25%
Patient Treatment
25%
Immune Checkpoint Inhibitors
25%
Therapeutic Targeting
25%
Treatment Modalities
25%
Clinical Benefit
25%
Promising Treatment
25%
Melanoma
25%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
25%
Predictive Biomarker
25%
Protein-ligand
25%
Immune Homeostasis
25%
Mutational Burden
25%
Immune Checkpoint
25%
Immunohistochemical Tests
25%
Protein Receptor
25%
Selection Response
25%
Immunologic Markers
25%
Clinical Trial Assay
25%
Medicine and Dentistry
Biological Marker
100%
Lung Cancer
100%
Programmed Death-Ligand 1
100%
Patient Selection
100%
Immunity
50%
Immunohistochemistry
33%
Clinical Trial
33%
Immunotherapy
33%
Programmed Death 1 Receptor
33%
Cancer Therapy
16%
Treatment Response
16%
Clear Cell Renal Cell Carcinoma
16%
Monotherapy
16%
Homeostasis
16%
Somatics
16%
T Cell
16%
Solid Malignant Neoplasm
16%
T Lymphocyte Receptor
16%
Tumor Microenvironment
16%
Clonal Variation
16%
CTLA-4
16%
Receptor Protein
16%
Protein Ligand
16%
Melanoma
16%
Biochemistry, Genetics and Molecular Biology
PD-L1
100%
Clinical Trial
33%
Immune Checkpoints
33%
Programmed Cell Death 1
33%
T Cell
16%
Homeostasis
16%
Clonality
16%
Clonal Variation
16%
T Cell Receptor
16%
Protein Ligand
16%
Immunity
16%
CTLA-4
16%
Immunology and Microbiology
Programmed Death-Ligand 1
100%
Immunity
50%
Immunotherapy
33%
Programmed Death 1 Receptor
33%
Homeostasis
16%
T Cell
16%
Carcinoma Cell
16%
T Cell Receptor
16%
Clonal Variation
16%
CTLA-4
16%